Literature DB >> 26093387

Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial.

Nikki McCaffrey1, Janet Hardy2, Belinda Fazekas3, Meera Agar4, Linda Devilee3, Debra Rowett5, David Currow6.   

Abstract

OBJECTIVE: The aim of the present study was to estimate the potential healthcare cost savings associated with reduced prescribing of subcutaneous ketamine for the treatment of chronic cancer pain after publication of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial (RCT), to provide further reasons to modify ketamine prescribing practice in this setting.
METHODS: Potential cost savings in this setting were estimated from a health system perspective using a 1-year impact model. The model was populated with estimates derived using an epidemiological approach informed by morbidity and prevalence data, the PaCCSC feasibility study, ketamine RCT and national ketamine utilisation survey results, as well as clinical opinion.
RESULTS: The total estimated annual hospitalisation costs associated with subcutaneous ketamine prescribing were A$3 899 600 (2605 bed-days). A 17% reduction in ketamine prescribing lowered hospitalisation costs to A$3 236 668 (2162 bed-days), a reduction of A$662 932 (443 bed-days) because of reduced in-patient stays associated with ketamine toxicity and prescribing process.
CONCLUSIONS: The findings from the modelled impact analysis suggest that dissemination of the PaCCSC ketamine RCT results may have saved the Australian healthcare system approximately A$663 000 in annual hospitalisation costs and freed up 443 in-patient bed-days, although there was high uncertainty within the study. Wider dissemination over time and targeted, local de-adoption strategies could result in further savings.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26093387     DOI: 10.1071/AH15012

Source DB:  PubMed          Journal:  Aust Health Rev        ISSN: 0156-5788            Impact factor:   1.990


  2 in total

1.  What is the likely impact on surgical site infections in Australian hospitals if smoking rates are reduced? A cost analysis.

Authors:  Nikki McCaffrey; Michelle Scollo; Emma Dean; Sarah L White
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

2.  Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide.

Authors:  Nikki McCaffrey; Tegan Asser; Belinda Fazekas; Wendy Muircroft; Meera Agar; Katherine Clark; Simon Eckermann; Jessica Lee; Rohit Joshi; Peter Allcroft; Caitlin Sheehan; David C Currow
Journal:  BMC Cancer       Date:  2020-10-31       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.